Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

August 01, 1995; Volume 48,Issue 2
  • You have access
    Agonist-dependent phosphorylation of the mouse delta-opioid receptor: involvement of G protein-coupled receptor kinases but not protein kinase C.
    G Pei, B L Kieffer, R J Lefkowitz and N J Freedman
    Molecular Pharmacology August 1995, 48 (2) 173-177;
  • You have access
    Pharmacological characterization of heterologously expressed ATP-gated cation channels (P2x purinoceptors).
    R J Evans, C Lewis, G Buell, S Valera, R A North and A Surprenant
    Molecular Pharmacology August 1995, 48 (2) 178-183;
  • You have access
    Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one.
    J Garthwaite, E Southam, C L Boulton, E B Nielsen, K Schmidt and B Mayer
    Molecular Pharmacology August 1995, 48 (2) 184-188;
  • You have access
    Antisense oligodeoxynucleotide to the Gi2 protein alpha subunit sequence inhibits an opioid-induced increase in the intracellular free calcium concentration in ND8-47 neuroblastoma x dorsal root ganglion hybrid cells.
    T Tang, J G Kiang, T E Côté and B M Cox
    Molecular Pharmacology August 1995, 48 (2) 189-193;
  • You have access
    alpha-Conotoxin ImI exhibits subtype-specific nicotinic acetylcholine receptor blockade: preferential inhibition of homomeric alpha 7 and alpha 9 receptors.
    D S Johnson, J Martinez, A B Elgoyhen, S F Heinemann and J M McIntosh
    Molecular Pharmacology August 1995, 48 (2) 194-199;
  • You have access
    Increased basal phosphorylation of the constitutively active serotonin 2C receptor accompanies agonist-mediated desensitization.
    R S Westphal, J R Backstrom and E Sanders-Bush
    Molecular Pharmacology August 1995, 48 (2) 200-205;
  • You have access
    Regulation of beta 2-adrenergic receptor mRNA and gene transcription in rat C6 glioma cells: effects of agonist, forskolin, and protein synthesis inhibition.
    K Hosoda, L R Fitzgerald, V A Vaidya, G K Feussner, P H Fishman and R S Duman
    Molecular Pharmacology August 1995, 48 (2) 206-211;
  • You have access
    Hormonal and cell density regulation of hepatic gamma-glutamylcysteine synthetase gene expression.
    J Cai, W M Sun and S C Lu
    Molecular Pharmacology August 1995, 48 (2) 212-218;
  • You have access
    Human brain-specific L-proline transporter: molecular cloning, functional expression, and chromosomal localization of the gene in human and mouse genomes.
    S Shafqat, M Velaz-Faircloth, V A Henzi, K D Whitney, T L Yang-Feng, M F Seldin and R T Fremeau
    Molecular Pharmacology August 1995, 48 (2) 219-229;
  • You have access
    5-Hydroxytryptamine2A receptors expressed in rat renal mesangial cells inhibit cyclic AMP accumulation.
    M N Garnovskaya, C G Nebigil, J M Arthur, R F Spurney and J R Raymond
    Molecular Pharmacology August 1995, 48 (2) 230-237;
  • You have access
    Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
    J R Spitzner, I K Chung, T D Gootz, P R McGuirk and M T Muller
    Molecular Pharmacology August 1995, 48 (2) 238-249;
  • You have access
    KMD-3213, a novel, potent, alpha 1a-adrenoceptor-selective antagonist: characterization using recombinant human alpha 1-adrenoceptors and native tissues.
    K Shibata, R Foglar, K Horie, K Obika, A Sakamoto, S Ogawa and G Tsujimoto
    Molecular Pharmacology August 1995, 48 (2) 250-258;
  • You have access
    Characterization of phorbol ester binding to protein kinase C isotypes.
    S M Dimitrijević, W J Ryves, P J Parker and F J Evans
    Molecular Pharmacology August 1995, 48 (2) 259-267;
  • You have access
    The low efficacy gamma-aminobutyric acid type A agonist 5-(4-piperidyl)isoxazol-3-ol opens brief Cl- channels in embryonic rat olfactory bulb neurons.
    U Kristiansen, J L Barker and R Serafini
    Molecular Pharmacology August 1995, 48 (2) 268-279;
  • You have access
    Characterization of (+/-)(-)[3H]epibatidine binding to nicotinic cholinergic receptors in rat and human brain.
    R A Houghtling, M I Dávila-García and K J Kellar
    Molecular Pharmacology August 1995, 48 (2) 280-287;
  • You have access
    Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
    J Priller, E M Briley, J Mansouri, W A Devane, K Mackie and C C Felder
    Molecular Pharmacology August 1995, 48 (2) 288-292;
  • You have access
    Agonist-mediated activation of phosphatidylcholine-specific phospholipase C and D in intestinal smooth muscle.
    K S Murthy and G M Makhlouf
    Molecular Pharmacology August 1995, 48 (2) 293-304;
  • You have access
    Determinants of sensitivity to 1-beta-D-arabinofuranosylcytosine in HCT 116 and NCI-H630 human colon carcinoma cells.
    J L Grem, F Geoffroy, P M Politi, D P Cuddy, D D Ross, D Nguyen, S M Steinberg and C J Allegra
    Molecular Pharmacology August 1995, 48 (2) 305-315;
  • You have access
    Analysis of the role of receptor number in defining the intrinsic activity and potency of partial agonists in neuroblastoma x glioma hybrid NG108-15 cells transfected to express differing levels of the human beta 2-adrenoceptor.
    D J MacEwan, G D Kim and G Milligan
    Molecular Pharmacology August 1995, 48 (2) 316-325;
  • You have access
    Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs.
    L L Habeck, L G Mendelsohn, C Shih, E C Taylor, P D Colman, L S Gossett, T A Leitner, R M Schultz, S L Andis and R G Moran
    Molecular Pharmacology August 1995, 48 (2) 326-333;
  • You have access
    Characterization of drug resistance mediated via the suppression of apoptosis by Abelson protein tyrosine kinase.
    R S Chapman, A D Whetton, C M Chresta and C Dive
    Molecular Pharmacology August 1995, 48 (2) 334-343;
  • You have access
    Characterization of a chimeric human dopamine D3/D2 receptor functionally coupled to adenylyl cyclase in Chinese hamster ovary cells.
    D H Van Leeuwen, J Eisenstein, K O'Malley and R G MacKenzie
    Molecular Pharmacology August 1995, 48 (2) 344-351;
  • You have access
    Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
    D M Slipetz, G P O'Neill, L Favreau, C Dufresne, M Gallant, Y Gareau, D Guay, M Labelle and K M Metters
    Molecular Pharmacology August 1995, 48 (2) 352-361;
  • You have access
    Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors.
    S Lazareno and N J Birdsall
    Molecular Pharmacology August 1995, 48 (2) 362-378;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 48, Issue 2
1 Aug 1995
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics